Co-Authors
This is a "connection" page, showing publications co-authored by Sean Pitroda and Rohan Katipally.
Connection Strength
3.259
-
Nontumor Cells in Tumor Samples Bias Expression-Based Models-Reply. JAMA Oncol. 2024 Feb 01; 10(2):260-261.
Score: 0.945
-
STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
Score: 0.877
-
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1245-1254.
Score: 0.230
-
Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition. Clin Cancer Res. 2023 08 01; 29(15):2761-2766.
Score: 0.228
-
A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy. NPJ Precis Oncol. 2022 Oct 14; 6(1):72.
Score: 0.216
-
The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
Score: 0.212
-
Linear accelerator-based stereotactic radiosurgery for glossopharyngeal neuralgia is safe and effective - Report of two cases. J Radiosurg SBRT. 2022; 8(2):151-153.
Score: 0.205
-
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
Score: 0.061
-
Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease. J Clin Oncol. 2024 Oct 10; 42(29):3387-3391.
Score: 0.061
-
Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1519-1530.
Score: 0.059
-
RNA m6A methylation and MDSCs: Roles and therapeutic implications for radiotherapy. Med. 2023 Dec 08; 4(12):863-874.
Score: 0.058
-
Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
Score: 0.054
-
Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
Score: 0.053